




Innovative Hypertrophic Cardiomyopathy Board at University Hospitals Harrington Heart & Vascular Institute Features Diverse Set of Experts

Complex condition best treated with a truly multidisciplinary approach


As the most common form of inherited heart disease, hypertrophic cardiomyopathy is hardly an unusual diagnosis for heart and vascular specialists. Research shows that it affects from one in 250 to one in 500 Americans, affecting hundreds of thousands of people. It's the single biggest cause behind sudden cardiac death in young people.

Yet caring for these patients effectively is anything but simple. The 2020 guidelines for the condition issued by the American Heart Association and American College of Cardiology, for example, are multifaceted and quite complex, say experts who treat the condition. Another indicator of complexity? The U.S. Food and Drug Administration requires that physicians pass a specialized test before they can prescribe the newly approved drug for obstructive hypertrophic cardiomyopathy, mavacamten (Camzyos).

Recognizing the challenge and complexity inherent in hypertrophic cardiomyopathy, the heart and vascular specialists at University Hospitals Harrington Heart & Vascular Institute have developed an approach to care that maximizes the input of the different cardiovascular disciplines within the Institute. Modeling themselves after an oncology tumor board, they've formed a hypertrophic cardiomyopathy board to manage these challenging patients. The multidisciplinary board includes specialists in heart failure, electrophysiology, cardiothoracic surgery, cardiovascular imaging, genetics, cardiovascular medicine, interventional cardiology and pediatric cardiology. Questions discussed include a patient's participation in athletics, the risk of sudden cardiac death and the need for an ICD, and which septal reduction technique is most warranted – surgical myectomy or alcohol ablation.

The article features Eiran Gorodeski, MD, MPH and Judith Mackall, MD.

[Click here to read the full article >](#)



Virtual Town Hall on COVID-19: Will It Ever End?

Held Wednesday, August 3rd

Hosted by **Daniel I. Simon, MD**, President, Academic & External Affairs and Chief Scientific Officer and joined by **Robert Salata, MD, FACP, FIDSA**, STERIS Chair of Excellence in Medicine, Professor and Chairman, Department of Medicine, CWRU, Physician-in-Chief, Master Clinician in Infectious Diseases, UH Cleveland Medical Center.

As COVID-19 continues to mutate and evolve, we realize you have questions about how best to care for our patients and for each other. And we recognize that the duration of the pandemic leaves you weary and worried about whether it will ever end.

Look for the recording link on the Digital Workplace as well as in the UH News and UH4YOU newsletters. As of this posting, the recording is not yet available (8/10/22).



Department of Medicine Annual Report

The 2021 Department of Medicine Annual Report is now available. Click below to view an electronic version (PDF) of the annual report.

[Click here to read the report >](#)

Awards - Appointments - Publications



US News Rankings

Cardiology and Geriatrics rank in the top 50, Cancer and Gastroenterology high-performing.

Specialties within the Department of Medicine at UH Cleveland Medical Center ranked in the Top 50 nationally; Cardiology & Heart Surgery (38) and Geriatrics (46). Cancer and Gastroenterology and GI Surgery were designated as high-performing. U.S. News also named UH Cleveland Medical Center as high-performing for 16 common adult procedures and conditions

[Click here to view UHMC's rankings](#)



Historical Neighborhood Redlining and Contemporary Cardiometabolic Risk

UH researchers find near century-old redlining discriminatory housing policies leave lasting legacy on modern day heart health

The idea that people of low-income experience shorter life spans and higher rates of chronic disease does not necessarily come as much of a surprise. So it's not shocking that living in a low-income neighborhood would also increase your chances of illness and premature death.

However, researchers from University Hospitals in Cleveland recently took it a step further, demonstrating that, among the many predictors of cardiovascular disease - one of them is whether your address falls in one of the neighborhoods that long ago was affected by discriminatory lending practices known as redlining.

"What's surprising to me is that every city that I've looked into, there is significant residential segregation. ... And no matter where you look, the relationship holds between the grading of the neighborhood (loan) risk and cardiometabolic health," said the study's lead author, **Dr. Sadeer Al-Kindi**, a cardiologist at University Hospitals.

[PubMed Article](#)

Authors: Issam Motairek, Eun Kyung Lee, Scott Janus, Michael Farkouh, Darcy Freedman, Jackson Wright, Khurram Nasir, Sanjay Rajagopalan, Sadeer Al-Kindi

[Read the full Cleveland.com article](#)

Research News



Case Western Reserve-led study identifies way to specifically target and block disease-associated white blood cells

Offers potential to transform therapies for prevalent diseases, including diabetic complications, cancer and autoimmune disorders

Neutrophils are a type of white blood cell that help fight illness and disease by traveling to the body's infected site to seek and destroy harmful pathogens.

But left unrestricted, neutrophils can also prolong inflammation and contribute to the development of conditions like vascular thrombosis, cancer and diabetic retinopathy.

To block the defensive cell's harmful effects, a research team led by Case Western Reserve University (CWRU) has designed a nanoparticle platform that can exclusively target disease-associated activated neutrophils—while leaving inactive circulating neutrophils untouched.

"It ensures that the disease-associated neutrophils are suppressed," **CWRU professor Evi Stavrou** explained, "but [their] ability to fight infections remains intact."

The findings offer the potential to transform therapies for prevalent diseases, including diabetic complications, cancer and autoimmune disorders.

[Read the full article here.](#)



Dr. Subauste Receives R01

Dr. Carlos Subauste received his third R01. It is from the NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases.

The research relates to the small molecule inhibitor of CD40-TRAF2 that was found by **Dr. Subauste**. This inhibitor markedly reduced intestinal inflammation in 3 mouse models of IBD. It also reduced CD40-driven pro-inflammatory responses in intestinal cells from IBD patients. The R01 will support optimization of the inhibitor.

Welcome to the Department



Param Singh, DO
Rheumatology Division



Marwa Sabha, MD
Rheumatology Division



Carla Greene
Associate Program
Administrator
Hematology/Oncology
Fellowship

Upcoming Events

Medicine Grand Rounds

September 13 - **Revital Gorodeski Baskin, MD**
Director, Obesity Center
Clinical and Molecular Endocrinology
"TBD"

Medicine Grand Rounds

September 20 - **Eiran Z. Gorodeski, MD, MPH, FACC, FHFSA**
Medical Director of the Advanced Heart Failure & Transplant Center
Cardiovascular Medicine
Professor, CWRU School of Medicine
"TBD"

Recurring Events (Zoom information sent out weekly)

Tuesdays @ Noon - **Medicine Grand Rounds Seminar Series** (September - May)
Wednesdays @ Noon - **VA M&M Conference**
Fridays @ Noon - **UH M&M Conference**


Recent Medicine Grand Rounds



[View](#)

Edgar Lerma, MD,
FACP


"Approaches to
Prevent and Treat
Chronic Hyperkalemia"



[View](#)

Celina Cunanan,
MSN & Patrick
Runnels, MD

"Won't You Be My
Neighbor? UH's Role in
Addressing SDOH to
Achieve Health Equity
in Cleveland"



[View](#)

Siba P
Raychaudhuri, MD

"T Cell Targeted
Therapies in
Autoimmune
Diseases"



[View](#)

Marjorie Greenfield,
MD

"Career Development
and Academic
Promotion"